We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
- Authors
Slagter, Astrid E.; Jansen, Edwin P. M.; van Laarhoven, Hanneke W. M.; van Sandick, Johanna W.; van Grieken, Nicole C. T.; Sikorska, Karolina; Cats, Annemieke; Muller-Timmermans, Pietje; Hulshof, Maarten C. C. M.; Boot, Henk; Los, Maartje; Beerepoot, Laurens V.; Peters, Frank P. J.; Hospers, Geke A. P.; van Etten, Boudewijn; Hartgrink, Henk H.; van Berge Henegouwen, Mark I.; Nieuwenhuijzen, Grard A. P.; van Hillegersberg, Richard; van der Peet, Donald L.
- Abstract
<bold>Background: </bold>Although radical surgery remains the cornerstone of cure in resectable gastric cancer, survival remains poor. Current evidence-based (neo)adjuvant strategies have shown to improve outcome, including perioperative chemotherapy, postoperative chemoradiotherapy and postoperative chemotherapy. However, these regimens suffer from poor patient compliance, particularly in the postoperative phase of treatment. The CRITICS-II trial aims to optimize preoperative treatment by comparing three treatment regimens: (1) chemotherapy, (2) chemotherapy followed by chemoradiotherapy and (3) chemoradiotherapy.<bold>Methods: </bold>In this multicentre phase II non-comparative study, patients with clinical stage IB-IIIC (TNM 8th edition) resectable gastric adenocarcinoma are randomised between: (1) 4 cycles of docetaxel+oxaliplatin+capecitabine (DOC), (2) 2 cycles of DOC followed by chemoradiotherapy (45Gy in combination with weekly paclitaxel and carboplatin) or (3) chemoradiotherapy. Primary endpoint is event-free survival, 1 year after randomisation (events are local and/or regional recurrence or progression, distant recurrence, or death from any cause). Secondary endpoints include: toxicity, surgical outcomes, percentage radical (R0) resections, pathological tumour response, disease recurrence, overall survival, and health related quality of life. Exploratory endpoints include translational studies on predictive and prognostic biomarkers.<bold>Discussion: </bold>The aim of this study is to select the most promising among three preoperative treatment arms in patients with resectable gastric adenocarcinoma. This treatment regimen will subsequently be compared with the standard therapy in a phase III trial.<bold>Trial Registration: </bold>clinicaltrials.gov NCT02931890 ; registered 13 October 2016. Date of first enrolment: 21 December 2017.
- Subjects
STOMACH cancer treatment; ONCOLOGIC surgery; CHEMORADIOTHERAPY; CANCER chemotherapy; PERIOPERATIVE care; DOCETAXEL; OXALIPLATIN; THERAPEUTICS; ANTINEOPLASTIC agents; COMBINED modality therapy; COMPARATIVE studies; GASTRECTOMY; LONGITUDINAL method; RESEARCH methodology; MEDICAL cooperation; METASTASIS; QUALITY of life; RESEARCH; RESEARCH funding; STOMACH tumors; TUMOR classification; EVALUATION research; RANDOMIZED controlled trials; TREATMENT effectiveness; TUMOR grading; TUMOR treatment
- Publication
BMC Cancer, 2018, Vol 18, Issue 1, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-018-4770-2